Evidence mapPaperPMID 40275681Full record

ArticleJournal of cachexia, sarcopenia and muscle2025

Walking Speed and Risk of Cancer in Two Prospective Cohort Studies.

Jonathan K L Mak, Kathryn Choon Beng Tan, Juulia Jylhävä, Sara Hägg, Ching-Lung Cheung

Abstract read
In one paragraph

Article in Journal of cachexia, sarcopenia and muscle, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jonathan K L MakDepartment of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, SAR, China.ORCID https://orcid.org/0000-0003-4454-8580
Kathryn Choon Beng TanDepartment of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, SAR, China.ORCID https://orcid.org/0000-0001-9037-0416
Juulia JylhäväDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.ORCID https://orcid.org/0000-0003-0250-4491
Sara HäggDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.ORCID https://orcid.org/0000-0002-2452-1500
Ching-Lung CheungDepartment of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, SAR, China.ORCID https://orcid.org/0000-0002-6233-9144

Funding

Instrumentarium Science Foundation, and the Signe and Ane Gyllenberg Foundation 6226Research Council of Finland 3493358Sigrid Jusélius Foundation, the Yrjö Jahnsson Foundation 20217416Swedish Cancer Society 21 1571 PjSwedish Research Council 2018-02077Swedish Research Council 2019-01272Swedish Research Council 2020-06101Swedish Research Council 2022-01608
6 · The paper itself

Abstract

backgroundWalking speed is a reliable marker of sarcopenia and a strong predictor of mortality, but its relationship with cancer incidence remains largely unexplored. We aimed to investigate the association between walking speed and the risk of any cancer and five common cancers, including lung, breast, colorectum, prostate, and stomach, and to explore potential mediation by biomarkers of inflammation, and lipid and glucose metabolism.

methodsThe primary analysis was conducted in 431 598 participants from the UK Biobank (mean age 56.3 [SD 8.1] years at baseline), and the generalizability of findings was further tested in 1311 participants from the Hong Kong Osteoporosis Study (HKOS; mean age 57.8 [SD 11.9] years). Walking speed was self-reported in the UK Biobank and measured using a timed 6-m walk test in the HKOS. Incident cancer cases were identified from electronic health records. We used Cox models, adjusted for age, sex, height, body mass index, socioeconomic, lifestyle factors, family history of cancer, and grip strength, to estimate the association between walking speed and cancer incidence. Single and multiple mediator models were performed in the UK Biobank to examine the mediating effects of C-reactive protein (CRP), white blood cell (WBC) count, total cholesterol, low-density lipoprotein (LDL) cholesterol, and glucose levels.

resultsOver a median follow-up of 10.9 and 6.9 years, 11.7% and 5.0% of the UK Biobank and HKOS participants were diagnosed with cancer, respectively. In the UK Biobank, those reported a brisk vs. slow walking pace had a 13% lower risk of any cancer (95% CI 0.84-0.90). Similarly, HKOS participants with a faster walking speed (≥ 1.0 vs. < 1.0 m/s) had a 45% reduced risk of any cancer (95% CI 0.31-0.98). In the UK Biobank, brisk walking pace was associated with a significantly decreased risk of lung cancer (hazard ratio [HR] 0.47, 95% CI 0.42-0.53) and a slightly increased risk of prostate cancer (HR 1.11, 95% CI 1.02-1.21). CRP, WBC count, total cholesterol, and LDL cholesterol significantly mediated the association between brisk walking pace and any cancer, with proportions of mediation being 6.4% (95% CI 4.4-8.7%), 11.4% (8.4-17.1%), 9.3% (7.1-12.9%), and 8.3% (6.1-11.9%), respectively. The combined mediated proportion of all five potential mediators was 25.9% (19.5-37.2%).

conclusionFaster walking speed, whether self-reported or measured, is associated with a reduced risk of cancer development. This association appears to be partially mediated by lower inflammation and improved lipid profiles.

Indexed as

NeoplasmsWalking SpeedAgedFemaleHumansIncidenceMaleMiddle AgedProspective StudiesRisk FactorsUnited Kingdomcancercohort studygait speedphysical activitysarcopenia

Identifiers

PMID40275681
PMCPMC12022227

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.